

**CHARACTERISING THE ROLE OF SUBSTANCE P
IN ACUTE ISCHAEMIC STROKE**

RENÉE JADE TURNER

B.Sc (Hons)

Discipline of Pathology, School of Medical Sciences

The University of Adelaide

November 2007

A thesis submitted to the University of Adelaide in fulfilment of the requirements
for the degree of Doctor of Philosophy

REFERENCES

- Afrah AW, Stiller CO, Olgart L, Brodin E, Gustafsson H. Involvement of spinal N-methyl-D-aspartate receptors in capsaicin-induced in vivo release of substance P in the rat dorsal horn. *Neurosci Lett*. 2001; 316:83-6.
- Agardh CD, Kalimo H, Olsson Y, Siesjo BK. Hypoglycemic brain injury: metabolic and structural findings in rat cerebellar cortex during profound insulin-induced hypoglycemia and in the recovery period following glucose administration. *J Cereb Blood Flow and Metab* 1981; 1:71-84.
- Alberts MJ, Bergman DL, Molner E, Jovanovic BD, Ushiwata I, Teruya J. Antiplatelet effect of aspirin in patients with cerebrovascular disease. *Stroke* 2004; 35: 175.
- Altura BM. Calcium Antagonist Properties of Magnesium: Implications for Antimigraine Actions. *Magnesium* 1985; 4: 169-175.
- Alves RV, Campos MM, Santos AR, Calixto JB. Receptor subtypes involved in tachykinin-mediated edema formation. *Peptides* 1999; 20: 921-7.
- Amantea D, Russo R, Gliozi M, Fratto V, Berliocchi L, Bagetta G, et al. Early upregulation of matrix metalloproteinases following reperfusion triggers neuroinflammatory mediators in brain ischemia in rat. *Int Rev Neurobiol* 2007; 82: 149-69.
- Aoki T, Sumii T, Mori T, Wang X, Lo EH. Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: mechanical versus embolic focal ischemia in spontaneously hypertensive rats. *Stroke* 2002; 33: 2711-7.
- Aronowski J, Ostrow P, Samways E, Strong R, Zivin JA, Grotta JC. Graded bioassay for demonstration of brain rescue from experimental acute ischemia in rats. *Stroke* 1994; 25:2235-40.
- Aronowski J, Samways E, Strong R, Rhoades HM, Grotta JC. An alternative method for the quantitation of neuronal damage after experimental middle cerebral artery occlusion in rats: analysis of behavioral deficit. *J Cereb Blood Flow Metab* 1996; 16: 705-13.
- Aronowski J, Strong R, Grotta JC. Reperfusion injury: demonstration of brain damage produced by reperfusion after transient focal ischemia in rats. *J Cereb Blood Flow Metab* 1997; 17: 1048-56.
- Asahi M, Asahi K, Wang X, Lo EH. Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats. *J Cereb Blood Flow Metab* 2000; 20: 452-7.
- Asahi M, Wang X, Mori T, Sumii T, Jung JC, Moskowitz MA, et al. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. *J Neurosci* 2001; 21: 7724-32.
- Auer RN, Kalimo H, Olsson Y, Siesjo BK. The temporal evolution of hypoglycemic brain damage. I. Light- and electron-microscopic findings in the rat cerebral cortex. *Acta Neuropathol (Berl)*. 1985; 67:13-24.

Auer RN, Olsson Y, Siesjo BK. Hypoglycemic brain injury in the rat. Correlation of density of brain damage with the EEG isoelectric time: a quantitative study. *Diabetes*. 1984; 33:1090-8.

Australian Bureau of Statistics.

Awtry EH, Loscalzo J. Aspirin. *Circulation* 2000; 101: 1206-18.

Ayata C, Ropper AH. Ischaemic brain oedema. *J Clin Neurosci* 2002; 9: 113-24.

Azaryan AV, Galoyan AA. Substrate specificity of cerebral cathepsin D and high-Mr aspartic endopeptidase. *J Neurosci Res* 1988; 192:268-71.

Bae YC, Oh JM, Hwang SJ, Shigenaga Y, Valschanoff JG. Expression of vanilloid receptor TRPV1 in the rat trigeminal sensory nuclei. *J Comp Neurol* 2004; 478: 62-71.

Bakhai A. The burden of coronary, cerebrovascular and peripheral arterial disease. *Pharmacoconomics* 2004; 22 Suppl 4: 11-8.

Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. *Neurology* 2001; 56:1015-20.

Barnett HJM. Medical management of cerebral transient ischaemic attacks. In: Meyer JS and Shaw T, editors. *Diagnosis and management of stroke and TIAs*. California: Addison-Wesley Publishing Company, 1982: 123-154.

Barone FC, Kilgore K. Role of inflammation and cellular stress in brain injury and central nervous system diseases. *Clin Neurosci Res* 2006; 6: 329-356

Bar-Shavit Z, Goldman R, Stabinsky Y, Gottlieb P, Fridkin M, Teichberg VI, Blumberg S. Enhancement of phagocytosis - a newly found activity of substance P residing in its N-terminal tetrapeptide sequence. *Biochem Biophys Res Commun* 1980; 94:1445-51.

Bath PMW. Optimising homeostasis. In: Brown MM, editor. *Stroke*. Vol 56. London: The Royal Society of Medicine Press Limited, 2000: 422-435.

Bederson JB, Pitts LH, Germano SM, Nishimura MC, Davis RL, Bartkowski HM. Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. *Stroke* 1986a; 17: 1304-8.

Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. *Stroke* 1986b; 17: 472-6.

Belayev L, Alonso OF, Busto R, Zhao W, Ginsberg MD. Middle cerebral artery occlusion in the rat by intraluminal suture. Neurological and pathological evaluation of an improved model. *Stroke* 1996a; 27: 1616-22; discussion 1623.

Belayev L, Busto R, Zhao W, Ginsberg MD. Quantitative evaluation of blood-brain barrier permeability following middle cerebral artery occlusion in rats. *Brain Res* 1996b; 739: 88-96.

Benchenane K, Berezowski V, Ali C, Fernandez-Monreal M, Lopez-Atalaya JP, Brillault J, et al. Tissue-type plasminogen activator crosses the intact blood-brain barrier by

low-density lipoprotein receptor-related protein-mediated transcytosis. *Circulation* 2005; 111: 2241-9.

Benjamin EJ, Plehn JF, D'Agostino RB, Belanger AJ, Comai K, Fuller DL, et al. Mitral annular calcification and the risk of stroke in an elderly cohort. *N Engl J Med* 1992; 327: 374-9.

Bennett GW, Ballard TM, Watson CD, Fone KC. Effect of neuropeptides on cognitive function. *Exp Gerontol* 1997; 32: 451-69.

Benoliel R, Tanaka M, Caudle RM, Iadarola MJ. Co-localization of N-methyl-D-aspartate receptors and substance P (neurokinin-1) receptors in rat spinal cord. *Neurosci Lett*. 2000; 291:61-4.

Bereczki D, Liu M, Prado GF, Fekete I. Cochrane report: A systematic review of mannitol therapy for acute ischemic stroke and cerebral parenchymal hemorrhage. *Stroke* 2000; 31:2719-22.

Bertrand C, Geppetti P, Baker J, Petersson G, Piedimonte G, Nadel JA. Role of peptidases and NK1 receptors in vascular extravasation induced by bradykinin in rat nasal mucosa. *J Appl Physiol* 1993; 74: 2456-61.

Bertrand E, Brouillet E, Caille I, Bouillot C, Cole GM, Prochiantz A, et al. A short cytoplasmic domain of the amyloid precursor protein induces apoptosis In Vitro and In Vivo. *Mol Cell Neurosci* 2001; 18: 503-511.

Beyreuther K, Multhaup G, Monning U, Sandbrink R, Beher D, Hesse L, et al. Regulation of APP expression, biogenesis and metabolism by extracellular matrix and cytokines. *Ann NY Acad Sci* 1996; 777: 74-76.

Black PH. Stress and the inflammatory response: a review of neurogenic inflammation. *Brain Behav Immun* 2002; 16: 622-53.

Blumberg S, Teichberg VI, Charli JL, Hersh LB, McKelvy JF. Cleavage of substance P to an N-terminal tetrapeptide and a C-terminal heptapeptide by a post-proline Cleaving enzyme from bovine brain. *Brain Res* 1980; 192: 477-86.

Blumbers PC, Scott G, Manavis J, Wainwright H, Simpson DA, McLean AJ. Staining of amyloid precursor protein to study axonal damage in mild head injury. *Lancet* 1994; 344: 1055-6.

Blumbers PC, Scott G, Manavis J, Wainwright H, Simpson DA, McLean AJ. Topography of axonal injury as defined by amyloid precursor protein and the sector scoring method in mild and severe closed head injury. *J Neurotrauma* 1995; 12: 565-72.

Bondy B, Baghai TC, Minov C, Schule C, Schwarz MJ, Zwanzger P, et al. Substance P serum levels are increased in major depression: preliminary results. *Biol Psychiatry* 2003; 53: 538-42.

Bovolenta P, Wandosell F, Nieto-Sampedro M. CNS glial scar tissue: a source of molecules which inhibit central neurite outgrowth. *Prog Brain Res* 1992; 94:367-79.

Bowes MP, Rothlein R, Fagan SC, Zivin JA. Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic injury and enhance efficacy of thrombolytic therapy. *Neurology* 1995; 45:815-9.

Boyce S, Smith D, Carlson E, Hewson L, Rigby M, O'Donnell R, et al. Intra-amygda-
injection of the substance P [NK(1) receptor] antagonist L-760735 inhibits neonatal
vocalisations in guinea-pigs. *Neuropharmacology* 2001; 41: 130-7.

Bracci-Laudiero L, Aloe L, Lundeberg T, Theodorsson E, Stenfors C. Altered levels of
neuropeptides characterize the brain of lupus prone mice. *Neurosci Lett* 1999;
275:57-60.

Brain SD. Sensory neuropeptides: their role in inflammation and wound healing.
Immunopharmacology 1997; 37: 133-52.

Braun JS, Jander S, Schroeter M, Witte OW, Stoll G. Spatiotemporal relationship of
apoptotic cell death to lymphomonocytic infiltration in photochemically induced
focal ischemia of the rat cerebral cortex. *Acta Neuropathol (Berl)* 1996; 92: 255-63.

Breen KC, Bruce M, Anderton BH. Beta amyloid precursor protein mediates neuronal cell-
cell and cell-surface adhesion. *J Neurosci Res* 1991; 28: 90-100.

Brierly JB, Brown AW. Remarks on papers by C.-D. Agardh et al/H.Kamilo et al.
"Hypoglycemic brain injury, I, II." *Acta Neuropathol* 1981; 55.

Brodal P. Nervous system structure and function. New York: Oxford University Press,
1998.

Broderick JP, Brott T, Tomsick T, Huster G, Miller R. The risk of subarachnoid and
intracerebral hemorrhages in blacks as compared with whites. *N Engl J Med* 1992;
326: 733-6.

Broderick JP, Hacke W. Treatment of acute ischemic stroke: Part II: neuroprotection and
medical management. *Circulation* 2002; 106: 1736-40.

Broderick JP, Hacke W. Treatment of acute ischemic stroke: Part II: neuroprotection and
medical management. *Circulation*. 2002; 106:1736-40.

Brott T, Adams HP, Jr., Olinger CP, Marler JR, Barsan WG, Biller J, et al. Measurements
of acute cerebral infarction: a clinical examination scale. *Stroke* 1989; 20: 864-70.

Bruno G, Tega F, Bruno A, Graf U, Corelli F, Molfetta R, et al. The role of substance P in
cerebral ischemia. *Int J Immunopathol Pharmacol* 2003; 16: 67-72.

Bucinskaite V, Brodda-Jansen G, Stenfors C, Theodorsson E, Lundeberg T. Increased
concentrations of calcitonin gene-related peptide-like immunoreactivity in rat brain
and peripheral tissue after ischaemia: correlation to flap survival. *Neuropeptides*
1998; 32: 179-83.

Bulloch K, Milner TA, Prasad A, Hsu M, Buzsaki G, McEwen BS. Induction of calcitonin
gene-related peptide-like immunoreactivity in hippocampal neurons following
ischemia: a putative regional modulator of the CNS injury/immune response. *Exp
Neurol* 1998; 150: 195-205.

Burchfiel CM, Curb JD, Rodriguez BL, Abbott RD, Chiu D, Yano K. Glucose intolerance
and 22-year stroke incidence. The Honolulu Heart Program. *Stroke* 1994; 25: 951-7.

Burggraaf D, Martens HK, Dichgans M, Hamann GF. rt-PA causes a dose-dependent
increase in the extravasation of cellular and non-cellular blood elements after focal
cerebral ischemia. *Brain Res* 2007; 1164: 55-62.

- Cammermeyer J. The importance of avoiding "dark" neurons in experimental neuropathology. *Acta Neuropathol* 1961; 1: 245-270.
- Campos MM, Calixto JB. Neurokinin mediation of edema and inflammation. *Neuropeptides* 2000; 34: 314-22.
- Candelario-Jalil E, Gonzalez-Falcon A, Garcia-Cabrera M, Leon OS, Fiebich BL. Wide therapeutic time window for nimesulide neuroprotection in a model of transient focal cerebral ischemia in the rat. *Brain Res* 2004; 1007: 98-108.
- Cao C, Lawrence DA, Li Y, Von Arnim CA, Herz J, Su EJ, Makarova A, Hyman B, Strickland DK, Zhang L. *EMBO J* 2006; 25: 1860-70.
- Cao T, Gerard NP, Brain SD. Use of NK(1) knockout mice to analyze substance P-induced edema formation. *Am J Physiol* 1999; 277: R476-81.
- Carrasco GA, Van de Kar LD. Neuroendocrine pharmacology of stress. *Eur J Pharmacol* 2003; 463: 235-72.
- Castro-Obregon S, Del Rio G, Chen SF, Swanson RA, Frankowski H, Rao RV, et al. A ligand-receptor pair that triggers a non-apoptotic form of programmed cell death. *Cell Death Differ* 2002; 9: 807-17.
- Chen H, Chopp M, Schultz L, Bodzin G, Garcia JH. Sequential neuronal and astrocytic changes after transient middle cerebral artery occlusion in the rat. *J Neurol Sci*. 1993; 118:109-6.
- Chen Y, Swanson RA. Astrocytes and brain injury. *J Cereb Blood Flow Metab* 2003; 23: 137-49.
- Choi DW. Calcium and excitotoxic neuronal injury. *Ann NY Acad Sci* 1994; 747: 162-171.
- Choi DW. Excitotoxic cell death. *J Neurobiol* 1992; 23: 1261-1276.
- Cinelli P, Madani R, Tsuzuki N, Vallet P, Arras M, Zhao CN, et al. Neuroserpin, a neuroprotective factor in focal ischemic stroke. *Mol Cell Neurosci* 2001; 18: 443-57.
- Cioni C, Renzi D, Calabro A, Annunziata P. Enhanced secretion of substance P by cytokine-stimulated rat brain endothelium cultures. *J Neuroimmunol* 1998; 84: 76-85.
- Clark RK, Lee EV, Fish CJ, White RF, Price WJ, Jonak ZL, Feuerstein GZ, Barone. Co-localization of N-methyl-D-aspartate receptors and substance P (neurokinin-1) receptors in rat spinal cord. *Neurosci Lett* 2000; 291:61-4.
- Copin JC, Gasche Y. Matrix metalloproteinase-9 deficiency has no effect on glial scar formation after transient focal cerebral ischemia in mouse. *Brain Res* 2007; 1150: 167-73.
- Corbett D, Nurse S. The problem of assessing effective neuroprotection in experimental cerebral ischemia. *Prog Neurobiol* 1998; 54: 531-48.
- Cramer SC, Chopp M. Recovery recapitulates ontogeny. *Trends Neurosci* 2000; 23: 265-71.

- Cyrino LA, Cardoso RC, Hackl LP, Nicolau M. Effect of quercetin on plasma extravasation in rat CNS and dura mater by ACE and NEP inhibition. *Phytother Res* 2002; 16: 545-9.
- Dam TV, Quirion R. Pharmacological characterization and autoradiographic localization of substance P receptors in guinea pig brain. *Peptides* 1986; 7: 855-64.
- Datta H, Rafter P, Chen Z, Wimalawansa S, Macintyre I. Amylin-amide displays a proliferative effect on human umbilical vein endothelial cells. *Biochem Soc Trans* 1990; 18:1276.
- De Giorgio R, Tazzari PL, Barbara G, Stanghellini V, Corinaldesi R. Detection of substance P immunoreactivity in human peripheral leukocytes. *J Neuroimmunol* 1998; 82: 175-81.
- De Girolami U, Frosch MP, Anthony DC. The central nervous system. In: R C, Cotran, V K and T C, editors. Robbins pathologic basis of disease. Philadelphia: W. B. Saunders Company, 1999: 1293-1357.
- del Zoppo GJ, Hallenbeck JM. Advances in the vascular pathophysiology of ischemic stroke. *Thromb Res*. 2000; 98:73-81.
- Delgado AV, McManus AT, Chambers JP. Production of tumor necrosis factor-alpha, interleukin 1-beta, interleukin 2, and interleukin 6 by rat leukocyte subpopulations after exposure to substance P. *Neuropeptides* 2003; 37: 355-61.
- Dembinski A, Warzecha Z, Ceranowicz P, Jaworek J, Sendur R, Knafel A, et al. Stimulation of sensory nerves and CGRP attenuate pancreatic damage in ischemia/reperfusion induced pancreatitis. *Med Sci Monit* 2003; 9: BR418-25.
- DeVries AC, Nelson RJ, Traystman RJ, Hurn PD. Cognitive and behavioral assessment in experimental stroke research: will it prove useful? *Neurosci Biobehav Rev* 2001; 25: 325-42.
- Dewey HM, Thrift AG, Mihalopoulos C, Carter R, Macdonell RA, McNeil JJ, et al. Cost of stroke in Australia from a societal perspective: results from the North East Melbourne Stroke Incidence Study (NEMESIS). *Stroke* 2001; 32: 2409-16.
- Dianzani C, Collino M, Lombardi G, Garbarino G, Fantozzi R. Substance P increases neutrophil adhesion to human umbilical vein endothelial cells. *Br J Pharmacol* 2003; 139:1103-10.
- Dickerson LM, Carek PJ, Quattlebaum RG. Prevention of recurrent ischemic stroke. *Am Fam Physician* 2007; 76: 382-388.
- Ding Y, Zhou Y, Lai Q, Li J, Gordon V, Diaz FG. Long-term neuroprotective effect of inhibiting poly (ADP-ribose) polymerase in rats with middle cerebral artery occlusion using a behavioral assessment. *Brain Res* 2001; 915: 210-7.
- Ding Y, Zhou Y, Lai Q, Li J, Park H, Diaz FG. Impaired motor activity and motor learning function in rat with middle cerebral artery occlusion. *Behav Brain Res* 2002; 132: 29-36.
- Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischemic stroke: an integrated review. *TINS* 1999; 22: 391-397.
- Dixon CE, Clifton GL, Lighthall JW, Yaghmai AA, Hayes RL. A controlled cortical impact model of traumatic brain injury in the rat. *J Neurosci Methods* 1991; 39: 253-262.

- Dobbin J, Crockard HA, Ross-Russell R. Transient blood-brain barrier permeability following profound temporary global ischaemia: an experimental study using ¹⁴C-AIB. *J Cereb Blood Flow Metab* 1989; 9: 71-8.
- Donkin JJ. The effects of the neuropeptide substance P in outcome following experimental traumatic brain injury. *University of Adelaide, Australia* 2006.
- Donkin JJ, Turner RJ, Hassan I, Vink R. Substance P in traumatic brain injury. *Prog Brain Res* 2007; 161: 97-109.
- Dragunow M, Sirimanne E, Lawlor PA, Williams C, Gluckman P. Accumulation of calcitonin-gene related peptide-like immunoreactivity after hypoxic-ischaemic brain injury in the infant rat. *Brain Res Mol Brain Res* 1992; 14: 267-72.
- Duffau H. Brain plasticity: From pathophysiological mechanisms to therapeutic applications. *J Clin Neurosci* 2006; 13: 885-897.
- Ebrahim S. Cost-effectiveness of stroke prevention. *Br Med Bull*. 2000; 56:557-70.
- Ebrahim S. Cost-effectiveness of stroke prevention. In: Brown MM, editor. *Stroke*. Vol 56. London: The Royal Society of Medicine Press Limited, 2000: 557-570.
- Fiebich BL, Schleicher S, Butcher RD, Craig A, Lieb K. The neuropeptide substance P activates p38 mitogen-activated protein kinase resulting in IL-6 expression independently from NF-kappa B. *J Immunol* 2000; 165: 5606-11.
- Fiebich BL, Schleicher S, Butcher RD, Craig A, Lieb K. The neuropeptide substance P activates p38 mitogen-activated protein kinase resulting in IL-6 expression independently from NF-kappa B. *J Immunol* 2000; 165:5606-11.
- Fitzgerald MJT, Folan-Curran J. Clinical Neuroanatomy and related neuroscience. Edinburgh: W.B. Saunders, 2002.
- Foell RB, Silver B, Merino JG, Wong EH, Demaerschalk BM, Poncha F, et al. Effects of thrombolysis for acute stroke in patients with pre-existing disability. *Cmaj* 2003; 169: 193-7.
- Fong TM, Yu H, Strader CD. The extracellular domain of substance P (NK1) receptor comprises part of the ligand binding site. *Biophys J* 1992; 62:59-60.
- Fournier A, Messerli FH, Achard JM, Fernandez L. Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials. *J Am Coll Cardiol* 2004; 43: 1343-7.
- Freed AL, Audus KL, Lunte SM. Investigation of the metabolism of substance P at the blood-brain barrier using capillary electrophoresis with laser-induced fluorescence detection. *Electrophoresis* 2001; 22: 3778-84.
- Freed AL, Cooper JD, Davies MI, Lunte SM. Investigation of the metabolism of substance P in rat striatum by microdialysis sampling and capillary electrophoresis with laser-induced fluorescence detection. *J Neurosci Methods* 2001; 109:23-9.
- Fu D, Ng YK, Gan P, Ling EA. Permanent occlusion of the middle cerebral artery upregulates expression of cytokines and neuronal nitric oxide synthase in the spinal cord and urinary bladder in the adult rat. *Neuroscience* 2004; 125: 819-31.
- Gamache FW. Comparison of global and focal ischemia. In: Wood JH, editor. *Cerebral blood flow*. New York: McGraw-Hill Book Company, 1987: 518-530.

Garcia JH, Liu KF, Ho KL. Neuronal necrosis after middle cerebral artery occlusion in Wistar rats progresses at different time intervals in the caudoputamen and the cortex. *Stroke* 1995a; 26: 636-42; discussion 643.

Garcia JH, Wagner S, Liu KF, Hu XJ. Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats. Statistical validation. *Stroke* 1995b; 26: 627-34; discussion 635.

Garcia JH, Yoshida Y, Chen H, Li Y, Zhang ZG, Lian J, Chen S, Chopp M. Progression from ischemic injury to infarct following middle cerebral artery occlusion in the rat. *Am J Pathol* 1993; 142:623-35.

Gartshore G, Patterson J, Macrae IM. Influence of ischemia and reperfusion on the course of brain tissue swelling and blood-brain barrier permeability in a rodent model of transient focal cerebral ischemia. *Exp Neurol* 1997; 147: 353-60.

Gavioli EC, Canteras NS, De Lima TC. The role of lateral septal NK1 receptors in mediating anxiogenic effects induced by intracerebroventricular injection of substance P. *Behav Brain Res* 2002; 134: 411-5.

Gherardini G, Evans GR, Theodorsson E, Gurlek A, Milner SM, Palmer B, et al. Calcitonin gene-related peptide in experimental ischemia. Implication of an endogenous anti-ischemic effect. *Ann Plast Surg* 1996; 36: 616-20.

Ginsberg MD. Adventures in the pathophysiology of brain ischemia: penumbra, gene expression, neuroprotection: the 2002 Thomas Willis Lecture. *Stroke* 2003; 34: 214-23.

Giulian D, Silverman G. Solid-State Animal Detection System: Its Application to Open Field Activity and Freezing Behaviour. *Physiol Behav* 1975; 14: 109-112.

Gladman JRF. Improving long-term rehabilitation. In: Brown MM, editor. *Stroke*. Vol 56. London: The Royal Society of Medicine Press Limited, 2000: 495-500.

Gladstone DJ, Black SE, Hakim AM. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. *Stroke* 2002; 33: 2123-36.

Gravanis I, Tsirka SE. Tissue plasminogen activator and glial function. *Glia* 2005; 49: 177-83.

Green AR. Why do neuroprotective drugs that are so promising in animals fail in the clinic? An industry perspective. *Clin Exp Pharmacol Physiol* 2002; 29: 1030-4.

Groger M, Lebesgue D, Pruneau D, Relton J, Kim SW, Nussberger J, et al. Release of bradykinin and expression of kinin B2 receptors in the brain: role for cell death and brain edema formation after focal cerebral ischemia in mice. *J Cereb Blood Flow Metab* 2005; 25: 978-89.

Grotta JC, Pettigrew LC, Rosenbaum D, Reid C, Rhoades H, McCandless D. Efficacy and mechanism of action of a calcium channel blocker after global cerebral ischemia in rats. *Stroke* 1988; 19: 447-54.

Grotta JC, Picone CM, Ostrow PT, Strong RA, Earls RM, Yao LP, et al. CGS-19755, a competitive NMDA receptor antagonist, reduces calcium-calmodulin binding and improves outcome after global cerebral ischemia. *Ann Neurol* 1990; 27: 612-9.

Guo CJ, Douglas SD, Gao Z, Wolf BA, Grinspan J, Lai JP, et al. Interleukin-1beta upregulates functional expression of neurokinin-1 receptor (NK-1R) via NF-kappaB in astrocytes. *Glia* 2004; 48: 259-66.

Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, Fischer M, Furlan A, Kaste M, Lees KR, Soehngen M, Warach S; DIAS Study Group. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. *Stroke*. 2005; 36:66-73.

Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne MH, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) *JAMA* 1995; 274:1017-25.

Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. *Lancet* 1998; 352:1245-51.

Hademenos GJ, Massoud TF. Biophysical mechanisms of stroke. *Stroke* 1997; 28: 2067-77.

Hafström I, Gyllenhammar H, Palmlad J, Ringertz B. Substance P activates and modulates neutrophil oxidative metabolism and aggregation. *J Rheumatol* 1989; 16:1033-7.

Hakamata Y, Hanyu S, Kuroiwa T, Ito U. Brain edema associated with progressive selective neuronal death or impending infarction in the cerebral cortex. *Acta Neurochir Suppl* 1997; 70: 20-2.

Hallak M, Berman RF, Irtenkauf SM, Janusz CA, Cotton DB. Magnesium Sulphate Treatment Decreases N-Methyl-D-Aspartate Receptor Binding in the Rat Brain: AN Autoradiographic Study. *J Soc Gynecol Invest* 1994; 1: 25-30.

Hamm RJ, Pike BR, O'Dell DM, Lyeth BG, Jenkins LW. The Rotarod: An Evaluation of Its Effectiveness in Assessing Motor Deficits Following Traumatic Brain Injury. *J Neurotrauma* 1994; 11: 187-196.

Han B, Haley WE. Family caregiving for patients with stroke. Review and analysis. *Stroke* 1999; 30: 1478-85.

Hanley DF. Review of critical care and emergency approaches to stroke. *Stroke* 2003; 34: 362-4.

Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. *Lancet* 1998; 351: 1755-62.

Hardwick JC, Mawe GM, Parsons RL. Tachykinin-induced activation of non-specific cation conductance via NK3 neurokinin receptors in guinea-pig intracardiac neurones. *J Physiol* 1997; 504: 65-74.

Harrison S, Geppetti P. Substance p. *Int J Biochem Cell Biol* 2001; 33: 555-76.

Hasenohrl RU, Souza-Silva MA, Nikolaus S, Tomaz C, Brandao ML, Schwarting RK, et al. Substance P and its role in neural mechanisms governing learning, anxiety and functional recovery. *Neuropeptides* 2000; 34: 272-80.

- Heiss WD, Graf R, Wienhard K, Lottgen J, Saito R, Fujita T, et al. Dynamic penumbra demonstrated by sequential multitracer PET after middle cerebral artery occlusion in cats. *J Cereb Blood Flow Metab* 1994; 14: 892-902.
- Heiss WD, Thiel A, Grond M, Graf R. Which targets are relevant for therapy of acute ischemic stroke? *Stroke* 1999; 30: 1486-9.
- Hill MD, Hachinski V. Stroke treatment: time is brain. *Lancet* 1998; 352 Suppl 3: SIII10-4.
- Hokfelt T, Broberger C, Xu ZQ, Sergeyev V, Ubink R, Diez M. Neuropeptides--an overview. *Neuropharmacology* 2000; 39: 1337-56.
- Hokfelt T, Pernow B, Wahren J. Substance P: a pioneer amongst neuropeptides. *J Intern Med* 2001; 249: 27-40.
- Holland JP, Sydserff SG, Taylor WA, Bell BA. Calcitonin gene-related peptide reduces brain injury in a rat model of focal cerebral ischemia. *Stroke* 1994; 25: 2055-8; discussion 2058-9.
- Holzer P. Neurogenic vasodilatation and plasma leakage in the skin. *Gen Pharmacol* 1998; 30: 5-11.
- Hooper NM, Turner AJ. Isolation of two differentially glycosylated forms of peptidyl-dipeptidase A (angiotensin converting enzyme) from pig brain: a re-evaluation of their role in neuropeptide metabolism. *Biochem J* 1987; 241: 625-33.
- Horstmann S, Kalb P, Koziol J, Gardner H, Wagner S. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. *Stroke* 2003; 34:2165-70.
- Horwood JM, Ripley TL, Stephens DN. Evidence for disrupted NMDA receptor function in tissue plasminogen activator knockout mice. *Behav Brain Res* 2004; 150:127-38.
- Howard G, Anderson R, Sorlie P, Andrews V, Backlund E, Burke GL. Ethnic differences in stroke mortality between non-Hispanic whites, Hispanic whites, and blacks. The National Longitudinal Mortality Study. *Stroke* 1994a; 25: 2120-5.
- Howard G, Evans GW, Crouse JR, 3rd, Toole JF, Ryu JE, Tegeler C, et al. A prospective reevaluation of transient ischemic attacks as a risk factor for death and fatal or nonfatal cardiovascular events. *Stroke* 1994b; 25: 342-5.
- Hu DE, Easton AS, Fraser PA. TRPV1 activation results in disruption of the blood-brain barrier in the rat. *Br J Pharmacol* 2005; 146: 576-84.
- Hunter AJ, Hatcher J, Virley D, Nelson P, Irving E, Hadingham SJ, et al. Functional assessments in mice and rats after focal stroke. *Neuropharmacology* 2000; 39: 806-816.
- Huston JP, Hasenohrl RU. The role of neuropeptides in learning: focus on the neuropeptide substance P. *Behav Brain Res* 1995; 66:117-27.
- Hutchinson EC, Acheson EJ. Strokes: natural history, pathology and surgical treatment. Vol 4. London: W.B. Saunders, 1975.
- Inoue T, Shimizu H, Kaminuma T, Tajima M, Watabe K, Yoshimoto T. Prevention of cerebral vasospasm by calcitonin gene-related peptide slow-release tablet after subarachnoid hemorrhage in monkeys. *Neurosurgery* 1996; 39: 984-90.

- Irving EA, Bentley DL, Parsons AA. Assessment of white matter injury following prolonged focal cerebral ischaemia in the rat. *Acta Neuropathol (Berl)* 2001; 102: 627-35.
- Iseri LT, French JH. Magnesium: Nature's physiologic calcium blocker. *Am Heart J* 1984; 108: 188-193.
- Iso H, Jacobs DR, Jr., Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. *N Engl J Med* 1989; 320: 904-10.
- Ito U, Ohno K, Saganuma Y, Suzuki K, Inaba Y. Effect of steroid on ischemic brain edema. Analysis of cytotoxic and vasogenic edema occurring during ischemia and after restoration of blood flow. *Stroke* 1980; 11: 166-72.
- Jaillard A, Cornu C, Durieux A, Moulin T, Boutitie F, Lees KR, et al. Hemorrhagic transformation in acute ischemic stroke. The MAST-E study. MAST-E Group. *Stroke* 1999; 30: 1326-32.
- Jankovic J. Differential diagnosis of stroke. In: Meyer JS and Shaw T, editors. *Diagnosis and management of stroke and TIAs*. California: Addison-Wesley Publishing Company, 1982: 63-84.
- Jennett B, Bond M. Assessment of outcome after severe brain damage. *Lancet* 1975: 480-484.
- Jiang Q, Ewing JR, Ding GL, Zhang L, Zhang ZG, Li L, Whitton P, Lu M, Hu J, Li. Quantitative evaluation of BBB permeability after embolic stroke in rat using MRI. *J Cereb Blood Flow Metab*. 2005; 25:583-92.
- Johnston DC, Hill MD. The patient with transient cerebral ischemia: a golden opportunity for stroke prevention. *Cmaj* 2004; 170: 1134-7.
- Jones TH, Morawetz RB, Crowell RM, Marcoux FW, FitzGibbon SJ, DeGirolami U, et al. Thresholds of focal cerebral ischemia in awake monkeys. *J Neurosurg* 1981; 54: 773-82.
- Kahles T, Foerch C, Sitzer M, Schroeter M, Steinmetz H, Rami A, et al. Tissue plasminogen activator mediated blood-brain barrier damage in transient focal cerebral ischemia in rats: relevance of interactions between thrombotic material and thrombolytic agent. *Vascul Pharmacol* 2005; 43: 254-9.
- Kalsner S. The question of feedback at the somadendritic region and antidepressant drug action. *Brain Res Bull* 2000; 52:467-73.
- Kano T, Katayama Y, Tejima E, Lo EH. Hemorrhagic transformation after fibrinolytic therapy with tissue plasminogen activator in a rat thromboembolic model of stroke. *Brain Res* 2000; 854: 245-8.
- Kashiba H, Ueda Y, Senba E. Systemic capsaicin in the adult rat differentially affects gene expression for neuropeptides and neurotrophin receptors in primary sensory neurons. *Neuroscience* 1997; 76: 299-312.
- Kastrup A, Engelhorn T, Beaulieu C, de Crespiigny A, Moseley ME. Dynamics of cerebral injury, perfusion, and blood-brain barrier changes after temporary and permanent middle cerebral artery occlusion in the rat. *J Neurol Sci* 1999; 166: 91-9.

- Kaur J, Zhao Z, Klein GM, Lo EH, Buchan AM. The neurotoxicity of tissue plasminogen activator? *J Cereb Blood Flow Metab* 2004; 24: 945-63.
- Kavelaars A, Broeke D, Jeurissen F, Kardux J, Meijer A, Franklin R, et al. Activation of human monocytes via a non-neurokinin substance P receptor that is coupled to Gi protein, calcium, phospholipase D, MAP kinase, and IL-6 production. *J Immunol* 1994; 153: 3691-9.
- Kawachi I, Colditz GA, Stampfer MJ, Willett WC, Manson JE, Rosner B, et al. Smoking cessation in relation to total mortality rates in women. A prospective cohort study. *Ann Intern Med* 1993; 119: 992-1000.
- Kelly MA, Shuaib A, Todd KG. Matrix metalloproteinase activation and blood-brain barrier breakdown following thrombolysis. *Exp Neurol* 2006.
- Kent DM, Ruthazer R, Selker HP. Are some patients likely to benefit from recombinant tissue-type plasminogen activator for acute ischemic stroke even beyond 3 hours from symptom onset? *Stroke* 2003; 34: 464-7.
- Kidwell CS, Saver JL, Carneado J, Sayre J, Starkman S, Duckwiler G, Gobin YP, Jahan R, Vespa P, Villablanca JP, Liebeskind DS, Vinuela F. Predictors of hemorrhagic transformation in patients receiving intra-arterial thrombolysis. *Stroke* 2002; 33:717-24.
- Kim DK, Oh EK, Summers BA, Prabhakar NR, Kumar GK. Release of substance P by low oxygen in the rabbit carotid body: evidence for the involvement of calcium channels. *Brain Res* 2001; 892: 359-69.
- Klatzo I. Pathophysiological aspects of brain edema. *Acta Neuropathol (Berl)* 1987; 72: 236-9.
- Knight RA, Barker PB, Fagan SC, Li Y, Jacobs MA, Welch KM. Prediction of impending hemorrhagic transformation in ischemic stroke using magnetic resonance imaging in rats. *Stroke* 1998; 29: 144-51.
- Koizumi J, Nakazawa T, Yoshida Y: Reperfusible brain infarction model in the rat. Proceedings of the 10th Meeting of the Japanese Stroke Society, Kyoto, Japan, April 18-19, 1985, p 159.
- Koshiya K, Kato T, Tanaka R, Kato T. Brain peptidases: their possible neuronal and glial localization. *Brain Res* 1984; 324: 261-70.
- Kotila M, Numminen H, Waltimo O, Kaste M. Depression after stroke: results of the FINNSTROKE Study. *Stroke* 1998; 29: 368-72.
- Kramer JH, Phillips TM, Weglicki WB. Magnesium-deficiency-enhanced post-ischemic myocardial injury is reduced by substance P receptor blockade. *J Mol Cell Cardiol* 1997; 29: 97-110.
- Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. *Science* 1998; 281: 1640-5.
- Kristian T, Gido G, Kuroda S, Schutz A, Siesjo BK. Calcium metabolism of focal and penumbral tissues in rats subjected to transient middle cerebral artery occlusion. *Exp Brain Res* 1998; 120: 503-9.
- Kristian T, Siesjo BK. Calcium in ischemic cell death. *Stroke* 1998; 29: 705-18.

Kuroiwa T, Cahn R, Juhler M, Goping G, Campbell G, Klatzo I. Role of extracellular proteins in the dynamics of vasogenic brain edema. *Acta Neuropathol (Berl)* 1985a; 66: 3-11.

Kuroiwa T, Miyasaka N, Fengyo Z, Yamada I, Nakane M, Nagaoka T, et al. Experimental ischemic brain edema: morphological and magnetic resonance imaging findings. *Neurosurg Focus* 2007; 22: E11.

Kuroiwa T, Shibutani M, Okeda R. Blood-brain barrier disruption and exacerbation of ischemic brain edema after restoration of blood flow in experimental focal cerebral ischemia. *Acta Neuropathol (Berl)* 1988; 76: 62-70.

Kuroiwa T, Ting P, Martinez H, Klatzo I. The biphasic opening of the blood-brain barrier to proteins following temporary middle cerebral artery occlusion. *Acta Neuropathol (Berl)* 1985b; 68: 122-9.

Kuroiwa T, Ueki M, Chen Q, Suemasu H, Taniguchi I, Okeda R. Biomechanical characteristics of brain edema: the difference between vasogenic-type and cytotoxic-type edema. *Acta Neurochir Suppl (Wien)* 1994; 60:158-61.

Kwiatkowski TG, Libman RB, Frankel M, Tilley BC, Morgenstern LB, Lu M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. *N Engl J Med* 1999; 340: 1781-7.

Lapchak PA, Araujo DM, Song D, Wei J, Zivin JA. Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator. *Stroke* 2002 33: 1411-5.

Lapchak PA, Chapman DF, Zivin JA. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. *Stroke* 2000; 31: 3034-40.

Larrue V, von Kummer RR, Muller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). *Stroke* 2001; 32: 438-41.

Lassen NA, Astrup J. Ischemic Penumbra. In: Wood JH, editor. *Cerebral blood flow*. New York: McGraw-Hill Book Company, 1987: 458-466.

Latour LL, Kang DW, Ezzeddine MA, Chalela JA, Warach S. Early blood-brain barrier disruption in human focal brain ischemia. *Ann Neurol* 2004; 56: 468-77.

Lazovic J, Basu A, Lin, H-W, Rothstein RP, Krady JK, Smith MS, Levison SW. Neuroinflammation and both cytotoxic and vasogenic edema are reduced in interleukin-1 type 1 receptor-deficient mice conferring neuroprotection. *Stroke* 2005; 36: 2226-2231.

Lee JM, Grabb MC, Zipfel GJ, Choi DW. Brain tissue responses to ischemia. *J Clin Invest* 2000; 106: 723-31.

Lee JM, Zipfel GJ, Choi DW. The changing landscape of ischaemic brain injury mechanisms. *Nature* 1999; 399: A7-14.

- Lee SR, Guo SZ, Scannevin RH, Magliaro BC, Rhodes KJ, Wang X, et al. Induction of matrix metalloproteinase, cytokines and chemokines in rat cortical astrocytes exposed to plasminogen activators. *Neurosci Lett* 2007; 417: 1-5.
- Leeman SE, Ferguson SL. Substance P: an historical perspective. *Neuropeptides* 2000; 34: 249-54.
- Lees KR. Thrombolysis. In: Brown MM, editor. Stroke. Vol 56. London: The Royal Society of Medicine Press Limited, 2000: 389-400.
- Lehrmann E, Christensen T, Zimmer J, Diemer NH, Finsen B. Microglial and macrophage reactions mark progressive changes and define the penumbra in the rat neocortex and striatum after transient middle cerebral artery occlusion. *J Comp Neurol* 1997; 386:461-76.
- Leker RR, Shohami E. Cerebral ischemia and trauma-different etiologies yet similar mechanisms: neuroprotective opportunities. *Brain Res Brain Res Rev* 2002; 39: 55-73.
- Lever IJ, Grant AD, Pezet S, Gerard NP, Brain SD, Malcangio M. Basal and activity-induced release of substance P from primary afferent fibres in NK1 receptor knockout mice: evidence for negative feedback. *Neuropharmacology* 2003; 45: 1101-10.
- Levesque M, Wallman MJ, Parent R, Sik A, Parent A. Neurokinin-1 and neurokinin-3 receptors in primate substantia nigra. *Neurosci Res* 2007; 57: 362-71.
- Lewen A, Matz P, Chan PH. Free radical pathways in CNS injury. *J Neurotrauma* 2000; 17: 871-890.
- Lewis SB, Finnie JW, Blumbergs PC, Scott G, Manavis J, Brown C, et al. A head impact model of early axonal injury in the sheep. *J Neurotrauma* 1996; 13: 505-14.
- Li F, Irie K, Anwer MS, Fisher M. Delayed triphenyltetrazolium chloride staining remains useful for evaluating cerebral infarct volume in a rat stroke model. *J Cereb Blood Flow Metab* 1997; 17: 1132-5.
- Li F, Liu KF, Silva MD, Omae T, Sotak CH, Fenstermacher JD, et al. Transient and permanent resolution of ischemic lesions on diffusion-weighted imaging after brief periods of focal ischemia in rats: correlation with histopathology. *Stroke* 2000a; 31: 946-54.
- Li F, Omae T, Fisher M. Spontaneous hyperthermia and its mechanism in the intraluminal suture middle cerebral artery occlusion model of rats. *Stroke* 1999; 30: 2464-70; discussion 2470-1.
- Li Y, Chopp M, Chen J, Wang L, Gautam SC, Xu YX, et al. Intrastriatal transplantation of bone marrow nonhematopoietic cells improves functional recovery after stroke in adult mice. *J Cereb Blood Flow Metab* 2000b; 20: 1311-9.
- Li Y, Chopp M, Zhang ZG, Zhang RL. Expression of glial fibrillary acidic protein in areas of focal cerebral ischemia accompanies neuronal expression of 72-kDa heat shock protein. *J Neurol Sci* 1995;128: 134-42.
- Liao D, Myers R, Hunt S, Shahar E, Paton C, Burke G, et al. Familial history of stroke and stroke risk. The Family Heart Study. *Stroke* 1997; 28: 1908-12.

- Lieberman DN, Mody I. Substance P enhances NMDA channel function in hippocampal dentate gyrus granule cells. *J Neurophysiol* 1998; 80:113-9.
- Ling C, Zou T, Hsiao Y, Tao X, Chen ZL, Strickland S, Song H. Disruption of tissue plasminogen activator gene reduces macrophage migration. *Biochem Biophys Res Commun* 2006; 349:906-12.
- Liu D, Smith CL, Barone FC, Ellison JA, Lysko PG, Li K, Simpson IA. Astrocytic demise precedes delayed neuronal death in focal ischemic rat brain. *Brain Res Mol Brain Res* 1999; 68:29-41.
- Lo EH, Singhal AB, Torchilin VP, Abbott NJ. Drug delivery to damaged brain. *Brain Res Brain Res Rev* 2001; 38: 140-8.
- Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. *Stroke* 1989; 20: 84-91.
- Longstaff C, Thelwell C. Understanding the enzymology of fibrinolysis and improving thrombolytic therapy. *FEBS Lett* 2005; 579: 3303-9.
- Longstreth WT, Jr., Nelson LM, Koepsell TD, van Belle G. Cigarette smoking, alcohol use, and subarachnoid hemorrhage. *Stroke* 1992; 23: 1242-9.
- Lotz M, Vaughan JH, Carson DA. Effect of neuropeptides on production of inflammatory cytokines by human monocytes. *Science* 1988; 241:1218-21.
- Love S. Apoptosis and brain ischaemia. *Prog Neuropsychopharmacol Biol Psychiatry* 2003; 27: 267-82.
- Love S. Oxidative stress in brain ischemia. *Brain Pathol* 1999; 9: 119-31.
- Lundy FT, Linden GJ. Neuropeptides And Neurogenic Mechanisms In Oral And Periodontal Inflammation. *Crit Rev Oral Biol Med* 2004; 15: 82-98.
- Mabuchi T, Kitagawa K, Ohtsuki T, Kuwabara K, Yagita Y, Yanagihara T, et al. Contribution of microglia/macrophages to expansion of infarction and response of oligodendrocytes after focal cerebral ischemia in rats. *Stroke* 2000; 31: 1735-43.
- Maggi CA, Giachetti A, Dey RD, Said SI. Neuropeptides as regulators of airway function: vasoactive intestinal peptide and the tachykinins. *Physiol Rev* 1995; 75: 277-322.
- Maggi CA, Schwartz TW. The dual nature of the tachykinin NK1 receptor. *Trends Pharmacol Sci* 1997; 18: 351-5.
- Maggi CA. The mammalian tachykinin receptors. *Gen Pharmacol* 1995; 26: 911-44.
- Makarova A, Mikhailenko I, Bugge TH, List K, Lawrence DA, Strickland DK. The low density lipoprotein receptor-related protein modulates protease activity in the brain by mediating the cellular internalization of both neuroserpin and neuroserpin-tissue-type plasminogen activator complexes. *J Biol Chem* 2003; 278: 50250-8.
- Malcangio M, Bowery NG. Peptide autoreceptors: does an autoreceptor for substance P exist? *Trends Pharmacol Sci* 1999; 20: 405-7.
- Malcangio M, Fernandes K, Tomlinson DR. NMDA receptor activation modulates evoked release of substance P from rat spinal cord. *Br J Pharmacol* 1998 125:1625-6.

- Malcangio M, Ramer MS, Jones MG, McMahon SB. Abnormal substance P release from the spinal cord following injury to primary sensory neurons. *Eur J Neurosci* 2000;12: 397-9.
- Markowitz S, Saito K, Moskowitz MA. Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain. *J Neurosci* 1987; 7: 4129-36.
- Marler JR, Goldstein LB. Medicine. Stroke--tPA and the clinic. *Science* 2003; 301: 1677.
- Marriott DR, Wilkin GP, Wood JN. Substance P-induced release of prostaglandins from astrocytes: regional specialisation and correlation with phosphoinositol metabolism. *J Neurochem* 1991; 56: 259-65.
- Marvizón JC, Martínez V, Grady EF, Bennett NW, Mayer EA. Neurokinin 1 receptor internalization in spinal cord slices induced by dorsal root stimulation is mediated by NMDA receptors. *J Neurosci* 1997; 17:8129-36.
- Mary V, Wahl F, Uzan A, Stutzmann JM. Enoxaparin in experimental stroke: neuroprotection and therapeutic window of opportunity. *Stroke* 2001; 32: 993-9.
- Matsas R, Kenny AJ, Turner AJ. The metabolism of neuropeptides. The hydrolysis of peptides, including enkephalins, tachykinins and their analogues, by endopeptidase-24.11. *Biochem J* 1984; 223: 433-40.
- Mattson MP. Apoptotic and anti-apoptotic synaptic signaling mechanisms. *Brain Pathol* 2000; 10: 300-12.
- McCabe DJH, Brown MM. Prevention of ischaemic stroke - antiplatelets. In: Brown MM, editor. *Stroke*. Vol 56. London: The Royal Society of Medicine Press, 2000: 510-525.
- McIlwain KL, Merriweather MY, Yuva-Paylor LA, Paylor R. The use of behavioral test batteries: effects of training history. *Physiol Behav* 2001; 73:705-17.
- Meng W, Wang X, Asahi M, Kano T, Asahi K, Ackerman RH, et al. Effects of tissue type plasminogen activator in embolic versus mechanical models of focal cerebral ischemia in rats. *J Cereb Blood Flow Metab* 1999; 19: 1316-21.
- Menzies SA, Betz AL, Hoff JT. Contributions of ions and albumin to the formation and resolution of ischemic brain edema. *J Neurosurg* 1993; 78: 257-66.
- Meyer JS. Course, prognosis, and medical management of patients with acute stroke. In: Meyer JS and Shaw T, editors. *Diagnosis and management of stroke and TIAs*. California: Addison-Wesley Publishing Company, 1982: 155-176.
- Miyai I, Suzuki T, Kang J, Kubota K, Volpe BT. Middle cerebral artery stroke that includes the premotor cortex reduces mobility outcome. *Stroke* 1999; 30: 1380-3.
- Mobley WC, Neve RL, Prusiner SB, McKinley MP. Nerve growth factor increase mRNA level for the prion protein and the β amyloid protein precursor in developing hamster brain. *Proc Natl Acad Sci USA* 1988; 85: 9811-9815.
- Modo M, Sowinski P, Hodges H. Conditional discrimination learning in rats with global ischaemic brain damage. *Behav Brain Res* 2000a; 111: 213-21.
- Modo M, Stroemer RP, Tang E, Veizovic T, Sowniski P, Hodges H. Neurological sequelae and long-term behavioural assessment of rats with transient middle cerebral artery occlusion. *J Neurosci Methods* 2000b; 104: 99-109.

- Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribo M, Quintana M, Alvarez-Sabin J. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. *Circulation* 2003; 107:598-603.
- Moro MA, Cardenas A, Hurtado O, Leza JC, Lizasoain I. Role of nitric oxide after brain ischaemia. *Cell Calcium* 2004; 36: 265-75.
- Moya KL, Benowitz LI, Schneider GE, Allinquant B. The amyloid precursor protein is developmentally regulated and correlated with synaptogenesis. *Dev Biol* 1994; 161: 597-603.
- Nagai N, De Mol M, Lijnen HR, Carmeliet P, Collen D. Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. *Circulation* 1999; 99: 2440-4.
- Nedergaard M, Dirnagl U. Role of glial cells in cerebral ischemia. *Glia* 2005; 50: 281-6.
- Newby DE, McLeod AL, Uren NG, Flint L, Ludlam CA, Webb DJ, Fox KA, Boon NA. Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis. *Circulation* 2001; 103: 1936-1941.
- Newby DE, Wright RA, Labinjoh C, Ludlam CA, Fox KA, Boon NA, Webb DJ. Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. *Circulation*. 1999; 99:1411-5.
- Nimmo AJ, Cernak I, Heath DL, Hu X, Bennett CJ, Vink R. Neurogenic inflammation is associated with development of edema and functional deficits following traumatic brain injury in rats. *Neuropeptides* 2004; 38: 40-7.
- Ning M, Furie KL, Koroshetz WJ, Lee H, Barron M, Lederer M, Wang X, Zhu M, Sorensen AG, Lo EH, Kelly PJ. Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke. *Neurology* 2006; 66: 1550-5.
- Nolte J. The Human Brain an introduction to its functional anatomy. Vol 4th. St Louis: Mosby, 1999.
- Onteniente B, Couriaud C, Braudeau J, Benchoua A, Guegan C. The mechanisms of cell death in focal cerebral ischemia highlight neuroprotective perspectives by anti-caspase therapy. *Biochem Pharmacol* 2003; 66: 1643-9.
- Orr CF, Rowe DB, Halliday GM. An inflammatory review of Parkinson's disease. *Prog Neurobiol* 2002; 68: 325-40.
- Otsuka M, Yoshioka K. Neurotransmitter functions of mammalian tachykinins. *Physiol Rev* 1993; 73: 229-308.
- Palecek J, Paleckova V, Willis WD. Postsynaptic dorsal column neurons express NK1 receptors following colon inflammation. *Neuroscience* 2003; 116: 565-72.
- Palma C, Minghetti L, Astolfi M, Ambrosini E, Silberstein FC, Manzini S, Levi G, Aloisi F. Functional characterization of substance P receptors on cultured human spinal cord astrocytes: synergism of substance P with cytokines in inducing interleukin-6 and prostaglandin E2 production. *Glia* 1997; 21:183-93.

- Panicker JN, Thomas M, Pavithran K, Nair D, Sarma PS. Morbidity predictors in ischemic stroke. *Neurol India* 2003; 51: 49-51.
- Patacchini R, Maggi CA, Holzer P. Tachykinin autoreceptors in the gut. *Trends Pharmacol Sci* 2000; 21: 166.
- Paylor R, Spencer CM, Yuva-Paylor LA, Pieke-Dahl S. The use of behavioral test batteries, II: effect of test interval. *Physiol Behav* 2006; 85: 95-102.
- Pegorini S, Braida D, Verzoni C, Guerini-Rocco C, Consalez GG, Croci L, et al. Capsaicin exhibits neuroprotective effects in a model of transient global cerebral ischemia in Mongolian gerbils. *Br J Pharmacol* 2005; 144: 727-35.
- Persson L, Hardemark HG, Bolander HG, Hillered L, Olsson Y. Neurologic and neuropathologic outcome after middle cerebral artery occlusion in rats. *Stroke* 1989; 20: 641-645.
- Persson MG, Hedqvist P, Gustafsson LE. Nerve-induced tachykinin-mediated vasodilation in skeletal muscle is dependent on nitric oxide formation. *Eur J Pharmacol* 1991; 205: 295-301.
- Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, et al. Randomised trial of prophylactic daily aspirin in British male doctors. *Br Med J (Clin Res Ed)* 1988; 296: 313-6.
- Petty MA, Lo EH. Junctional complexes of the blood-brain barrier: permeability changes in neuroinflammation. *Prog Neurobiol* 2002; 68: 311-23.
- Petty MA, Wettstein JG. Elements of cerebral microvascular ischaemia. *Brain Res Brain Res Rev* 2001; 36: 23-34.
- Pfefferkorn T, Rosenberg GA. Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. *Stroke* 2003; 34: 2025-30.
- Phillis JW, O'Regan MH. The role of phospholipases, cyclooxygenases, and lipoxygenases in cerebral ischemic/traumatic injuries. *Crit Rev Neurobiol* 2003; 15: 61-90.
- Plummer P, Behrman AL, Duncan PW, Spigel P, Saracino D, Martin J, Fox E, Thigpen M, Kautz SA. Effects of stroke severity and training duration on locomotor recovery after stroke: a pilot study. *Neurorehabil Neural Repair* 2007; 21: 137-51.
- Polavarapu R, Gongora MC, Yi H, Ranganthan S, Lawrence DA, Strickland D, et al. Tissue-type plasminogen activator-mediated shedding of astrocytic low-density lipoprotein receptor-related protein increases the permeability of the neurovascular unit. *Blood* 2007; 109: 3270-8.
- Povlishock JT. Pathobiology of traumatically induced axonal injury in animal and man. *Ann Emerg Med* 1993; 22: 980-986.
- Povlishock JT. Traumatically induced axonal injury: pathogenesis and pathobiological implications. *Brain Pathol* 1992; 2(1): 1-12.
- Preston E, Sutherland G, Finsten A. Three openings of the blood-brain barrier produced by forebrain ischemia in the rat. *Neurosci Lett* 1993; 149: 75-8.
- Probert L, Hanley MR. The immunocytochemical localisation of 'substance-P-degrading enzyme' within the rat spinal cord. *Neurosci Lett* 1987; 78: 132-7.

Przyklenk K, Kloner RA. "Reperfusion injury" by oxygen-derived free radicals? Effect of superoxide dismutase plus catalase, given at the time of reperfusion, on myocardial infarct size, contractile function, coronary microvasculature, and regional myocardial blood flow. *Circ Res* 1989; 64:86-96.

Qizilbash N, Lewington SL, Lopez-Arrieta JM. Corticosteroids for acute ischaemic stroke. *Cochrane Database Syst Rev* 2002; 2:CD000064.

QJ, Knight RA, Chopp M. Quantitative evaluation of BBB permeability after embolic stroke in rat using MRI. *J Cereb Blood Flow Metab* 2005; 25:583-92.

Quast MJ, Huang NC, Hillman GR, Kent TA. The evolution of acute stroke recorded by multimodal magnetic resonance imaging. *Magn Reson Imaging* 1993; 11: 465-71.

Rafalowska J. Experimental and human ischaemia: is the penumbra present in human ischaemic stroke? *Folia Neuropathol* 2002; 40: 211-7.

Rahman S, Dobson PR, Bunning RA, Russell RG, Brown BL. The regulation of connective tissue metabolism by vasoactive intestinal polypeptide. *Regul Pept* 1992; 37:111-21.

Raivich G, Bohatschek M, Kloss CU, Werner A, Jones LL, Kreutzberg GW. Neuroglial activation repertoire in the injured brain: graded response, molecular mechanisms and cues to physiological function. *Brain Res Brain Res Rev* 1999; 30: 77-105.

Ramos C, Montano M, Cisneros J, Sommer B, Delgado J, Gonzalez-Avila G. Substance P up-regulates matrix metalloproteinase-1 and down-regulates collagen in human lung fibroblast. *Exp Lung Res* 2007; 33: 151-67.

Reed JC. Apoptosis-regulating proteins as targets for drug discovery. *Trends Mol Med* 2001; 7: 314-9.

Reglodi D, Somogyvari-Vigh A, Maderdrut JL, Vigh S, Arimura A. Postischemic spontaneous hyperthermia and its effects in middle cerebral artery occlusion in the rat. *Exp Neurol* 2000; 163: 399-407.

Reglodi D, Tamas A, Lengvari I. Examination of sensorimotor performance following middle cerebral artery occlusion in rats. *Brain Res Bull* 2003; 59: 459-66.

Regoli D, Boudon A, Fauchere JL. Receptors and antagonists for substance P and related peptides. *Pharmacol Rev* 1994; 46: 551-99.

Ribeiro-da-Silva A, Hokfelt T. Neuroanatomical localisation of Substance P in the CNS and sensory neurons. *Neuropeptides* 2000; 34: 256-71.

Richardson JD, Vasko MR. Cellular Mechanisms of Neurogenic Inflammation. *J Pharmacol Exp Ther* 2002; 302: 839-845.

Rijntjes M. Mechanisms of recovery in stroke patients with hemiparesis or aphasia: new insights, old questions and the meaning of therapies. *Curr Opin Neurol* 2006; 19:76-83.

Robertson GS, Crocker SJ, Nicholson DW, Schulz JB. Neuroprotection by the inhibition of apoptosis. *Brain Pathol* 2000; 10: 283-92.

Robertson SC, Lennarson P, Hasan DM, Traynelis VC. Clinical course and surgical management of massive cerebral infarction. *Neurosurgery* 2004; 551: 55-61.

- Rogers DC, Campbell CA, Stretton JL, Mackay KB. Correlation between motor impairment and infarct volume after permanent and transient middle cerebral artery occlusion in the rat. *Stroke* 1997; 28: 2060-5.
- Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. *Stroke* 1998; 29: 1020-30.
- Roof RL, Schielke GP, Ren X, Hall ED. A comparison of long-term functional outcome after 2 middle cerebral artery occlusion models in rats. *Stroke* 2001; 32: 2648-57.
- Rosenberg GA, Estrada EY, Dencoff JE. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. *Stroke* 1998; 29: 2189-95.
- Rosenberg GA, Yang Y. Vasogenic edema due to tight junction disruption by matrix metalloproteinases in cerebral ischemia. *Neurosurg Focus* 2007; 22: E4.
- Rosenberg GA. Ischemic brain edema. *Prog Cardiovasc Dis* 1999; 42: 209-16.
- Ross MH, Kaye GI, Pawlina W. Histology a text and atlas. Baltimore: Lippincott Williams and Wilkins, 2003.
- Rothman SM, Olney JW. Excitotoxicity and the NMDA receptor. *TINS* 1987; 10: 299-302.
- Rothwell PM. Who should have carotid surgery or angioplasty? *Br Med Bull* 2000; 56: 526-38.
- Ruff MR, Wahl SM, Pert CB. Substance P receptor-mediated chemotaxis of human monocytes. *Peptides* 1985; 6 (Suppl): 107-11.
- Rupniak NM, Carlson EC, Harrison T, Oates B, Seward E, Owen S, et al. Pharmacological blockade or genetic deletion of substance P (NK(1)) receptors attenuates neonatal vocalisation in guinea-pigs and mice. *Neuropharmacology* 2000; 39: 1413-21.
- Rupniak NM, Kramer MS. Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. *Trends Pharmacol Sci* 1999; 20: 485-90.
- Sacco RL, Benjamin EJ, Broderick JP, Dyken M, Easton JD, Feinberg WM, et al. Risk factors. *Stroke* 1997; 28: 1507-1517.
- Sacco RL, Shi T, Zamanillo MC, Kargman DE. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Stroke Study. *Neurology* 1994; 44: 626-34.
- Sacco RL, Wolf PA, Kannel WB, McNamara PM. Survival and recurrence following stroke. The Framingham study. *Stroke* 1982; 13: 290-5.
- Sachais BS, Snider RM, Lowe JA 3rd, Krause JE. Molecular basis for the species selectivity of the substance P antagonist CP-96,345. *J Biol Chem* 1993 Feb 5;268(4):2319-23.
- Sakurada T, Hara A, Matsumura H, Yamada H, Sakurada S, Kisara K. A substance P analogue reduces amino acid contents in the rat spinal cord. *Pharmacol Toxicol* 1990; 66: 75-6.
- Saladin KS. Anatomy and Physiology, the unity of form and function. New York: McGraw-Hill, 2001.

- Samsam M, Covenas R, Csillik B, Ahangari R, Yajeya J, Riquelme R, et al. Depletion of substance P, neurokinin A and calcitonin gene-related peptide from the contralateral and ipsilateral caudal trigeminal nucleus following unilateral electrical stimulation of the trigeminal ganglion; a possible neurophysiological and neuroanatomical link to generalized head pain. *J Chem Neuroanat* 2001; 21: 161-9.
- Saria A, Lundberg JM, Skofitsch G, Lembeck F. Vascular protein linkage in various tissue induced by substance P, capsaicin, bradykinin, serotonin, histamine and by antigen challenge. *Naunyn Schmiedebergs Arch Pharmacol* 1983; 324: 212-8.
- Saria A, Lundberg JM. Capsaicin pretreatment inhibits heat-induced oedema in the rat skin. *Naunyn Schmiedebergs Arch Pharmacol* 1983; 323: 341-2.
- Saria A. The tachykinin NK1 receptor in the brain: pharmacology and putative functions. *Eur J Pharmacol* 1999; 375: 51-60.
- Sarti C, Rastenye D, Cepaitis Z, Tuomilehto J. International trends in mortality from stroke, 1968 to 1994. *Stroke* 2000; 31: 1588-601.
- Schaller B, Graf R. Cerebral ischemia and reperfusion: the pathophysiologic concept as a basis for clinical therapy. *J Cereb Blood Flow Metab* 2004; 24: 351-71.
- Schallert T, Upchurch M, Lobaugh N, Farrar SB, Spirduso WW, Gilliam P, Vaughn D, Wilcox RE. Tactile extinction: distinguishing between sensorimotor and motor asymmetries in rats with unilateral nigrostriatal damage. *Pharmacol Biochem Behav* 1982; 16:455-62.
- Schallert T. Behavioral tests for preclinical intervention assessment. *NeuroRx* 2006; 3:497-504.
- Schiemanck SK, Post MW, Kwakkel G, Witkamp TD, Kappelle LJ, Prevo AJ. Ischemic lesion volume correlates with long-term functional outcome and quality of life of middle cerebral artery stroke survivors. *Restor Neurol Neurosci* 2005; 23: 257-63.
- Schmid-Elsaesser R, Zausinger S, Hungerhuber E, Baethmann A, Reulen HJ. A critical reevaluation of the intraluminal thread model of focal cerebral ischemia: evidence of inadvertent premature reperfusion and subarachnoid hemorrhage in rats by laser-Doppler flowmetry. *Stroke* 1998; 29: 2162-70.
- Schroeter M, Jander S, Huitinga I, Witte OW, Stoll G. Phagocytic response in photochemically induced infarction of rat cerebral cortex. The role of resident microglia. *Stroke* 1997; 28: 382-6.
- Schroeter M, Jander S, Witte OW, Stoll G.J Local immune responses in the rat cerebral cortex after middle cerebral artery occlusion. *Neuroimmunol* 1994; 55: 195-203.
- Schulz JB, Weller M, Moskowitz MA. Caspases as treatment targets in stroke and neurodegenerative diseases. *Ann Neurol* 1999; 45: 421-9.
- Schwab S, Spranger M, Schwarz S, Hacke W. Barbiturate coma in severe hemispheric stroke: useful or obsolete? *Neurology* 1997; 48: 1608-13.
- Serra MC, Bazzoni F, Della Bianca V, Greskowiak M, Rossi F. Activation of human neutrophils by substance P. Effect on oxidative metabolism, exocytosis, cytosolic Ca²⁺ concentration and inositol phosphate formation. *J Immunol* 1988; 141: 2118-24.

Severini C, Improta G, Falconieri-Erspamer G, Salvadori S, Erspamer V. The tachykinin peptide family. *Pharmacol Rev* 2002; 54: 285-322.

Shallert D, Wilcox RE. Tactile extinction: distinguishing between sensorimotor and motor asymmetries in rats with unilateral nigrostriatal damage. *Pharmacol Biochem Behav* 1982; 16: 455-62.

Sharma HS, Nyberg F, Thornwall M, Olsson Y. Met-enkephalin-Arg6-Phe7 in spinal cord and brain following traumatic injury to the spinal cord: influence of p-chlorophenylalanine. An experimental study in the rat using radioimmunoassay technique. *Neuropharmacology* 1993; 32: 711-7.

Sherwood L. Human Physiology: From Cells to Systems. Belmont: Wadsworth Publishing Company, 1997.

Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. *BMJ* 1989; 298: 789-94.

Siao CJ, Tsirka SE. Tissue plasminogen activator mediates microglial activation via its finger domain through annexin II. *J Neurosci* 2002; 22: 3352-8.

Siesjo BK, Agardh CD, Bengtsson F. Free radicals and brain damage. *Cerebrovasc Brain Metab Rev* 1996; 1: 165-211.

Sims NR, Anderson MF. Mitochondrial contributions to tissue damage in stroke. *Neurochem Int* 2002; 40: 511-26.

Skidgel RA, Erdos EG. Cleavage of peptide bonds by angiotensin I converting enzyme. *Agents Actions Suppl* 1987b; 22: 289-96.

Skidgel RA, Erdos EG. The broad substrate specificity of human angiotensin I converting enzyme. *Clin Exp Hypertens* 1987a; 9: 243-59.

Small DH, Nurcombe V, Reed G, Clarris H, Moir R, Beyreuther K, et al. A heparin-binding domain in the amyloid protein precursor of Alzheimer's disease is involved in the regulation of neurite outgrowth. *J Neurosci* 1994; 14: 2117-2127.

Small DL, Buchan AM. Animal models. *Br Med Bull* 2000; 56: 307-17.

Smith SE, Hodges H, Sowinski P, Man CM, Leach MJ, Sinden JD, et al. Long-term beneficial effects of BW619C89 on neurological deficit, cognitive deficit and brain damage after middle cerebral artery occlusion in the rat. *Neuroscience* 1997; 77: 1123-35.

Snider RM, Lowe JA. Nonpeptide substance P and other tachykinin receptor antagonists as a novel pharmacologic and therapeutic class. *Biol Psych* 1997; 42: 272s-273s.

Sood RR, Taheri S, Candelario-Jalil E, Estrada EY, Rosenberg GA. Early beneficial effect of matrix metalloproteinase inhibition on blood-brain barrier permeability as measured by magnetic resonance imaging countered by impaired long-term recovery after stroke in rat brain. *J Cereb Blood Flow Metab* 2007; In Press.

Souza DG, Mendonca VA, de ACMS, Poole S, Teixeira MM. Role of tachykinin NK receptors on the local and remote injuries following ischaemia and reperfusion of the superior mesenteric artery in the rat. *Br J Pharmacol* 2002; 135: 303-12.

- Stacey AE, Woodhall GL, Jones RS. Neurokinin-mediated depolarisation of cortical neurons elicits an increase in glutamate release at excitatory synapses. *Eur J Neurosci* 2002; 16: 1896-1906.
- Steenbergen C, Murphy E, Watts JA, London RE. Correlation between cytosolic free calcium, contracture, ATP, and irreversible ischemic injury in perfused rat heart. *Circ Res* 1990; 66:135-46.
- Stineman MG, Maislin G, Fiedler RC, Granger CV. A prediction model for functional recovery in stroke. *Stroke* 1997; 28: 550-6.
- Stöhr T, Schulte Wermeling D, Weiner I, Feldon J. Rat strain differences in open-field behavior and the locomotor stimulating and rewarding effects of amphetamine. *Pharmacol Biochem Behav* 1998; 4:813-8.
- Stoll G, Jander S, Schroeter M. Inflammation and glial responses in ischemic brain lesions. *Prog Neurobiol* 1998; 56: 149-71.
- Stoll G, Schroeter M. Cytokines in CNS disorders: neurotoxicity versus neuroprotection. In: K. Jellinger., R. Schmidt. and Winfisch. M, editors. Advances in dementia research. New York: Springer-Verlag, 2000: 81-89.
- Stone SP, Allder SJ, Gladman JRF. Predicting outcome in acute stroke. In: Brown MM, editor. Stroke. Vol 56. London: The Royal Society of Medicine Press Limited, 2000: 486-494.
- Strbian D, Karjalainen-Lindsberg ML, Tatlisumak T, Lindsberg PJ. Cerebral mast cells regulate early ischemic brain swelling and neutrophil accumulation. *J Cereb Blood Flow Metab* 2006; 26: 605-12.
- Stumm R, Culmsee C, Schafer MK, Kriegstein J, Weihe E. Adaptive plasticity in tachykinin and tachykinin receptor expression after focal cerebral ischemia is differentially linked to gabaergic and glutamatergic cerebrocortical circuits and cerebrovenular endothelium. *J Neurosci* 2001; 21: 798-811.
- Sumii T, Lo EH. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. *Stroke* 2002; 33: 831-6.
- Sutoo D, Yabe K, Akiyama K. Quantitative imaging of substance P in the human brain using a brain mapping analyzer. *Neurosci Res* 1999; 35: 339-46.
- Symon L. Pathological regulation in cerebral ischemia. In: Wood JH, editor. Cerebral blood flow. New York: McGraw-Hill Book Company, 1987: 413-424.
- Tejima E, Zhao BQ, Tsuji K, Rosell A, van Leyen K, Gonzalez RG, Montaner J, Wang X, Lo EH. Astrocytic induction of matrix metalloproteinase-9 and edema in brain hemorrhage. *J Cereb Blood Flow Metab*. 2007; 27:460-8.
- Thornton E, Vink R, Blumbergs PC, Van Den Heuvel C. Soluble amyloid precursor protein alpha reduces neuronal injury and improves functional outcome following diffuse traumatic brain injury in rats. *Brain Res* 2006; 1094: 38-46.
- Toomey JR, Valocik RE, Koster PF, Gabriel MA, McVey M, Hart TK, et al. Inhibition of factor IX(a) is protective in a rat model of thromboembolic stroke. *Stroke* 2002; 33: 578-85.

- Trendelenburg G, Dirnagl U. Neuroprotective role of astrocytes in cerebral ischemia: focus on ischemic preconditioning. *Glia* 2005; 50: 307-20.
- Tsirka SE. Clinical implications of the involvement of tPA in neuronal cell death. *J Mol Med* 1997; 75: 341-7.
- Turcanyi B, Toth B, Racz I, Vendegh Z, Furesz J, Hamar J. Ischemia reperfusion injury of the skeletal muscle after selective deafferentation. *Physiol Res* 2005; 54: 25-32.
- Turner RJ, Blumbergs PC, Sims NR, Helps SC, Rodgers KM, Vink R. Increased substance P immunoreactivity and edema formation following reversible ischemic stroke. *Acta Neurochir Suppl* 2006; 96: 263-6.
- Turner RJ, Dasilva KW, O'Connor C, van den Heuvel C, Vink R. Magnesium gluconate offers no more protection than magnesium sulphate following diffuse traumatic brain injury in rats. *J Am Coll Nutr* 2004; 23: 541S-544S.
- Turner RJ, Van den Heuvel C, Vink R. Amiloride increases neuronal damage after traumatic brain injury in rats. *J Am Coll Nutr* 2004; 23: 534S-537S.
- Turner RJ, Blumbergs PC, Sims NR, Helps SC, Rodgers KM, Vink R. Increased substance P immunoreactivity and edema formation following reversible ischemic stroke. *Acta Neurochir Suppl* 2006; 96:263-6.
- Turner RJ, Vink R. Inhibition of neurogenic inflammation as a novel treatment for ischaemic stroke. *Drug News and Perspectives* 2007; 20:221-226.
- Unal-Cevik I, Kilinc M, Can A, Gursoy-Ozdemir Y, Dalkara T. Apoptotic and necrotic death mechanisms are concomitantly activated in the same cell after cerebral ischemia. *Stroke* 2004; 35: 2189-94.
- Valtysson J, Hillered L, Andine P, Hagberg H, Persson L. Neuropathological endpoints in experimental stroke pharmacotherapy: the importance of both early and late evaluation. *Acta Neurochir (Wien)* 1994; 129: 58-63.
- Van de Werf F. Why is there so much geographic variation in clinical outcome in international trials of fibrinolytic therapy? *Eur Heart J* 2001; 22:1631-2.
- Van Den Heuvel C, Blumbergs P, Finnie J, Manavis J, Lewis S, Jones N, et al. Upregulation of amyloid precursor protein and its mRNA in an experimental model of paediatric head injury. *J Clin Neurosci* 2000b; 7: 140-145.
- Van Den Heuvel C, Blumbergs PC, Finnie JW, Manavis J, Jones NR, Reilly PL, et al. Upregulation of amyloid precursor protein messenger RNA in response to traumatic brain injury: an ovine head impact model. *Exp Neurol* 1999; 159: 441-50.
- Van Den Heuvel C, Finnie JW, Blumbergs PC, Manavis J, Jones NR, Reilly PL, et al. Upregulation of neuronal amyloid precursor protein (APP) and APP mRNA following magnesium sulphate ($MgSO_4$) therapy in traumatic brain injury. *J Neurotrauma* 2000a; 17: 1041-1053.
- Van Den Heuvel C, Lewis S, Wong M, Manavis J, Finnie JW, Blumbergs P, et al. Diffuse neuronal perikaryon amyloid precursor protein immunoreactivity in a focal head impact model. *Acta Neurochir Suppl (Wien)* 1998; 71: 209-211.
- van der Staay FJ, Augstein KH, Horvath E. Sensorimotor impairments in rats with cerebral infarction, induced by unilateral occlusion of the left middle cerebral artery: strain differences and effects of the occlusion site. *Brain Res* 1996; 735: 271-84.

- Vanderschueren S, Van Vlaenderen I, Collen D. Intravenous thrombolysis with recombinant staphylokinase versus tissue-type plasminogen activator in a rabbit embolic stroke model. *Stroke* 1997; 28: 1783-8.
- Venables GS. Anticoagulants. In: Brwon MM, editor. *Stroke*. Vol 56. London: The Royal Society of Medicine Press Limited, 2000: 501-509.
- Vink R, Young A, Bennett CJ, Hu X, Connor CO, Cernak I, et al. Neuropeptide release influences brain edema formation after diffuse traumatic brain injury. *Acta Neurochir Suppl* 2003;86:257-60.
- Virley D, Beech JS, Smart SC, Williams SC, Hodges H, Hunter AJ. A temporal MRI assessment of neuropathology after transient middle cerebral artery occlusion in the rat: correlations with behavior. *J Cereb Blood Flow Metab* 2000; 20: 563-82.
- Vivaldi MT, Kloner RA, Schoen FJ. Triphenyltetrazolium staining of irreversible ischemic injury following coronary artery occlusion in rats. *Am J Pathol* 1985; 121: 522-30.
- Wang LH, Ahmad S, Benter IF, Chow A, Mizutani S, Ward PE. Differential processing of substance P and neurokinin A by plasma dipeptidyl(amino)peptidase IV, aminopeptidase M and angiotensin converting enzyme. *Peptides* 1991; 12: 1357-64.
- Wang X, Asahi M, Lo EH. Tissue type plasminogen activator amplifies hemoglobin-induced neurotoxicity in rat neuronal cultures. *Neurosci Lett* 1999; 274: 79-82.
- Wang X, Lo EH. Astrocytic induction of matrix metalloproteinase-9 and edema in brain hemorrhage. *J Cereb Blood Flow Metab* 2007; 27: 460-8.
- Wang X, Lo EH. Astrocytic induction of matrix metalloproteinase-9 and edema in brain hemorrhage. *J Cereb Blood Flow Metab* 2007; 27:460-8.
- Wang X, Tsuji K, Lee SR, Ning M, Furie KL, Buchan AM, Lo EH. Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. *Stroke* 2004; 35:2726-30.
- Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG, Lipton SA. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in mice. *Nat Med* 1998; 4:228-31.
- Warach S, Latour LL. Evidence of reperfusion injury, exacerbated by thrombolytic therapy, in human focal brain ischemia using a novel imaging marker of early blood-brain barrier disruption. *Stroke* 2004; 35: 2659-61.
- Warlow CP. Epidemiology of stroke. *Lancet* 1998; 352 Suppl 3: SIII1-4.
- Watling KJ, Guard S. Tachykinin receptor agonists and antagonists. *Neurotransmissions* 1992; 8: 1-8.
- Weglicki WB. Intravenous magnesium gluconate for treatment of conditions caused by excessive oxidative stress due to free radical distribution. *US Patent 5, 843, 996*, 1998.
- Weinstein PR, Hong S, Sharp FR. Molecular identification of the ischemic penumbra. *Stroke* 2004; 35: 2666-70.
- Weinstock JV, Blum AM, Malloy T. Macrophages within the granulomas of murine *Schistosoma mansoni* are a source of a somatostatin 1-14-like molecule. *Cell Immunol* 1990; 131: 381-90.

- Whisnant JP. Effectiveness versus efficacy of treatment of hypertension for stroke prevention. *Neurology* 1996; 46: 301-7.
- Wilkinson PR, Wolfe CD, Warburton FG, Rudd AG, Howard RS, Ross-Russell RW, et al. A long-term follow-up of stroke patients. *Stroke* 1997; 28: 507-12.
- Williams LS, Weinberger M, Harris LE, Biller J. Measuring quality of life in a way that is meaningful to stroke patients. *Neurology* 1999; 53: 1839-43.
- Wimalawansa SJ. Calcitonin gene-related peptide and its receptors: molecular genetics, physiology, pathophysiology, and therapeutic potentials. *Endocr Rev* 1996; 17: 533-85.
- Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. *Stroke* 1991; 22: 983-8.
- Wolf PA, D'Agostino RB, Kannel WB, Bonita R, Belanger AJ. Cigarette smoking as a risk factor for stroke. The Framingham Study. *JAMA* 1988; 259: 1025-9.
- Wolf PA. Prevention of stroke. *Lancet*. 1998; 352:SIII15-8.
- World Health Organisation, 2004.
- Wu DM, van Zwieten PA, Doods HN. Effects of calcitonin gene-related peptide and BIBN4096BS on myocardial ischemia in anesthetized rats. *Acta Pharmacol Sin* 2001; 22:588-94.
- Wu LJ, Xu H, Ko SW, Yoshimura M, Zhuo M. Feed-forward inhibition: a novel cellular mechanism for the analgesic effect of substance P. *Mol Pain* 2005; 1: 34.
- Xu J, Xu F, Wang R, Seagrave J, Lin Y, March TH. Cigarette smoke-induced hypercapnic emphysema in C3H mice is associated with increases of macrophage metalloelastase and substance P in the lungs. *Exp Lung Res* 2007; 33: 197-215.
- Yam PS, Dunn LT, Graham DI, Dewar D, McCulloch J. NMDA receptor blockade fails to alter axonal injury in focal cerebral ischemia. *J Cereb Blood Flow Metab* 2000; 20: 772-9.
- Yam PS, Patterson J, Graham DI, Takasago T, Dewar D, McCulloch J. Topographical and quantitative assessment of white matter injury following a focal ischaemic lesion in the rat brain. *Brain Res Brain Res Protoc* 1998; 2: 315-22.
- Yamaguchi M, Kojima T, Kanekawa M, Aihara N, Nogimura A, Kasai K. Neuropeptides stimulate production of interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha in human dental pulp cells. *Inflamm Res* 2004; 53: 199-204.
- Yang DY, Pan HC, Chen CJ, Cheng FC, Wang YC. Effects of tissue plasminogen activator on cerebral microvessels of rats during focal cerebral ischemia and reperfusion. *Neurol Res* 2007; 29: 274-82.
- Yang GY, Betz AL. Reperfusion-induced injury to the blood-brain barrier after middle cerebral artery occlusion in rats. *Stroke* 1994; 25: 1658-64; discussion 1664-5.
- Yatsu FM, Pettigrew LC, Grotta JC. Medical therapeutics for acute ischemic stroke. In: Wood JH, editor. *Cerebral blood flow*. New York: McGraw-Hill Book Company, 1987: 603-609.

- Yepes M, Lawrence DA. Tissue-type plasminogen activator and neuroserpin: a well-balanced act in the nervous system? *Trends Cardiovasc Med* 2004; 14: 173-80.
- Yepes M, Sandkvist M, Moore EG, Bugge TH, Strickland DK, Lawrence DA. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. *J Clin Invest* 2003; 112: 1533-40.
- Yepes M, Sandkvist M, Wong MK, Coleman TA, Smith E, Cohan SL, et al. Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. *Blood* 2000; 96: 569-76.
- Yi JS, Kim YH, Koh JY. Infarct reduction in rats following intraventricular administration of either tissue plasminogen activator (tPA) or its non-protease mutant S478A-tPA. *Exp Neurol* 2004; 189: 354-60.
- Yoshimoto T, Ogawa A, Seki H, Kogure T, Suzuki J. Clinical course of acute middle cerebral artery occlusion. *J Neurosurg* 1986; 65: 326-30.
- Yu Z, Cheng G, Huang X, Li K, Cao X. Neurokinin-1 receptor antagonist SR140333: a novel type of drug to treat cerebral ischemia. *Neuroreport* 1997; 8: 2117-9.
- Zauner A, Muizelaar JP. Brain metabolism and blood flow. In: P R and R B, editors. Head Injury: Pathophysiology and management of severe closed injury. London: Chapman and Hall, 1997: 89-99.
- Zausinger S, Hungerhuber E, Baethmann A, Reulen H, Schmid-Elsaesser R. Neurological impairment in rats after transient middle cerebral artery occlusion: a comparative study under various treatment paradigms. *Brain Res* 2000; 863: 94-105.
- Zhang L, Zhang ZG, Zhang R, Morris D, Lu M, Coller BS, et al. Adjuvant treatment with a glycoprotein IIb/IIIa receptor inhibitor increases the therapeutic window for low-dose tissue plasminogen activator administration in a rat model of embolic stroke. *Circulation* 2003; 107: 2837-43.
- Zhang X, Polavarapu R, She H, Mao Z, Yepes M. Tissue-type plasminogen activator and the low-density lipoprotein receptor-related protein mediate cerebral ischaemia-induced nuclear factor- κ B pathway activation. *Am J Pathol* 2007; 171: 1281-90.
- Zhang Z, Zhang L, Yepes M, Jiang Q, Li Q, Arniego P, et al. Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke. *Circulation* 2002; 106: 740-5.
- Zhao BQ, Tejima E, Lo EH. Neurovascular proteases in brain injury, hemorrhage and remodeling after stroke. *Stroke* 2007; 38: 748-52.